ZLZhihui Liu

Zhihui Liu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zhihui Liu has a total of 12 co-authors. Here are the top co-authors by number of shared publications:

  • Changyuan Wei

    Department of Breast Surgery, Guangxi Medical University Cancer Hospital, Nanning, People’s Republic of China

    1 shared publication
  • Chong Huang

    Department of Gynecology, Wuhan Children's Hospital Affiliated by Tongji Medical College of Huazhong University of Science and Technology, Jiangan, Wuhan, Hubei, China

    1 shared publication
  • Huifeng Shi

    Department of Gynecology, The Second People's Hospital of Nanhai District, Pingzhou, Guicheng, Nanhai, Foshan, Guangdong, China

    1 shared publication
  • Jian-Hong Zhong

    Hepatobiliary Surgery Department, Guangxi Medical University Cancer Hospital, Nanning, China

    1 shared publication
  • Junbao Wei

    Department of Therapeutic Radiology

    1 shared publication
  • Meiqin Wu

    Department of Gynecology, Wuhan Children's Hospital Affiliated by Tongji Medical College of Huazhong University of Science and Technology, Jiangan, Wuhan, Hubei, China

    1 shared publication

Latest Publications

  • DDN‐AS1‐miR‐15a/16‐TCF3 feedback loop regulates tumor progression in cervical cancer

    by Zhihui Liu, Meiqin Wu, Huifeng Shi, Chong Huang, Sukun Luo, Xiaojie Song

    Cervical cancer (CC) is known as one of the most common gynecological tumors. Long noncoding RNAs (lncRNAs) are a group of regulators that have been widely reported in human malignant tumors including CC. On the basis of the data of The Cancer Genome Atlas, lncRNA DDN and PRKAG1 antisense RNA 1 ( DDN‐AS1) that is overexpressed in CC tissues predicted poor prognosis for patients with CC. Moreover, quantitative reverse transcription PCR analysis further identified the upregulation of DDN‐AS1 in CC tissues and cell lines. Loss‐of‐function assays revealed that knockdown of DDN‐AS1 suppressed CC progression by efficiently inhibiting cell proliferation, migration, and invasion. Mechanism investigations revealed that DDN‐AS1 was upregulated by its upstream transcription activator transcription factor 3 ( TCF3). Moreover, DDN‐AS1 increased the expression of TCF3 by competitively binding miR‐15a and miR‐16. In conclusion, DDN‐AS1‐miR‐15a/16‐TCF3 feedback loop contributes to cell proliferation, migration, and invasion in CC.


  • Open Access

    18F-FDG PET with or without CT in the diagnosis of extrahepatic metastases or local residual/recurrent hepatocellular carcinoma

    by Xiaoli Liao, Junbao Wei, Yongqiang Li, Jianhong Zhong, Zhihui Liu, Sina Liao, Qian Li, Changyuan Wei

    The aim of the present study was to meta-analyze the literature on the diagnostic value of 18-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) with or without computed tomography (CT) in detecting extrahepatic metastases or local residual/recurrent hepatocellular carcinoma (HCC). Systematic review of literature in MEDLINE, Embase, and Cochrane databases was conducted in March 2017, and relevant studies analyzing the diagnostic performance of 18F-FDG PET with or without CT were meta-analyzed. Meta-analysis was carried out on data from 11 studies involving 572 patients. 18F-FDG PET, with or without CT, showed pooled sensitivity of 64% and pooled specificity of 95%. Pooled sensitivity was similar with CT (74%) or without (52%; P = .279). Similarly, pooled specificity was comparable with CT (93%) or without 95% (P = .481). 18F-FDG PET, with or without CT, shows relatively low sensitivity but high specificity for diagnosing extrahepatic metastases or local residual/recurrent HCC. Adding CT to 18F-FDG PET may improve diagnostic performance, but the available evidence suggests that the improvement is not statistically significant.